Tower Research Capital LLC (Trc) An2 Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.53 Billion
- Q2 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,313 shares of ANTX stock, worth $5,631. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,313
Previous 2,082
155.19%
Holding current value
$5,631
Previous $2,000
150.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ANTX
# of Institutions
38Shares Held
7.58MCall Options Held
0Put Options Held
0-
Almitas Capital LLC Santa Monica, CA1.43MShares$1.51 Million0.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.1 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY583KShares$617,7360.62% of portfolio
-
Stonepine Capital Management, LLC Bend, OR544KShares$577,1630.57% of portfolio
-
Landscape Capital Management, L.L.C.495KShares$525,1190.05% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $20.6M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...